Reduced Relapse risk in patients with AML and NHL after HCMV-replication post haematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004300

Enrollment

200

Registered

2012-08-07

Start date

2012-08-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C92 C85

Interventions

Group 1: patients with NHL or AML in whom a CMV replication is documented after transplant Group 2: Patients with AML or NHL in whom a CMV replication is not documented after transplant

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patient's informed consent • No application of prophylactic ganciclovir or other CMV specific drugs or immunoglobuline preparations in the entire posttransplant course • regular at least once weekly monitoring of CMV pp65-antigenemia or CMV copy by PCR until day 120 after

Exclusion criteria

Exclusion criteria: • Relapsed or progressive malignant disease (other than minimal residual disease diagnosed by molecular methods) within 90 days after transplant • Severe uncontrolled infections

Design outcomes

Primary

Measure	Time frame
relapse rate, disease free survival at 24 months post transplant	—

Secondary

Measure	Time frame
overall survival, incidence of GVHD, none-relapse-mortality at 24 months post transplant	—

Countries

Germany

Contacts

Public ContactAhmet Elmaagacli

Uniklinik Essen Klinik für KMT

ahmet.elmaagacli@uk-essen.de0201-7233145

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 10, 2026